JOBEVNE

LaunchmAb

bevacizumab-nwgd

Biocon
BLAINJECTIONINJECTABLE
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100

Mechanism of Action

Vascular Endothelial Growth Factor-directed Antibody Interactions

Pharmacologic Class:

Vascular Endothelial Growth Factor Inhibitor

Company
B
Biocon
India - Bangalore
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers